Women's fertility appmaker Glow raised $17 million to expand upon its launch a year ago, just as at-home pregnancy monitoring player BellaBeat rolled out three new products. Both 1-year-old startups are backed by high-flying tech VCs and are making sophisticated, consumer-friendly products aimed at helping women better manage and monitor their health that circumvent traditional healthcare providers.
The digital health Q3 report was not to shabby, with steady growth rom Q2 and a total of $3 billion in funding.
Boehringer Ingelheim envisions some day selling day a smart inhaler that can tell patients when its medication is running low and remind them if they missed a prescheduled dose.
Philips was slapped with a $466 million verdict in its patent infringement battle with Masimo over technology used for its pulse oximeter devices, casting a pall over the company's recent restructuring and product development efforts.
Philips is getting serious about consumer health, staking the entire business on merging its healthcare and consumer units into one company focused on health tech. It will spin off the lighting business into a separate company next year.
The U.S. Department of Defense has bestowed $100 million in contracts with three med tech companies. The recent awardees include Abbott Laboratories, Impact Instrumentation and BrainScope. The BrainScope grant will go to further R&D for its traumatic brain injury assessment system, while the other two were for medical equipment.
The FDA announced that it has finalized its guidance on managing cybersecurity risks as it aims to protect patient privacy and prevent devices from malfunctioning due to computer viruses.
Breast cancer detection may soon leave 2-D mammography in the dust, embracing instead a more comprehensive diagnostic tool: 3-D technology.
Endo International is approaching the end of the road in its vaginal mesh saga, agreeing to pay $400 million to settle "substantially all" of the remaining suits related to its vaginal-mesh implants.
Acton, MA-based Cognoptix, developer of an eye test for diagnosing Alzheimer's, announced that it has closed a Series D financing round worth more than $15 million. It was lead by new investor Alopexx and existing investor Inventages. Original investor Launchpad Venture Group also participated.
The earliest awards from the U.S. National Institutes of Health in support of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, totaling $46 million in fiscal 2014, have been disclosed. The funding goes to more than 100 investigators in 15 locations in the U.S. and three nations.
Device advice was in abundance at today's Food and Drug Law Institute panel discussion on the industry's compliance with promotion and advertising regs, featuring prominent industry lawyers from Medtronic, Covidien, Abbott and law firms.
Investors were pleased that TransEnterix scored a few more quarters' worth of runway in a $25 million debt deal, sending shares up almost 7% in early trading. The minimally invasive surgical company expects to submit a 510(k) for its SurgiBot by year end.
GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with GE Healthcare to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.
iHealth launched three mobile health apps on Apple's HealthKit and announced the integration of 9 medical devices onto HealthKit, all programmed to work in the new iOS8.
As devicemakers cast an eye toward a lucrative sleep disorder market, Itamar Medical is joining the ranks and anticipating positive third-quarter results buoyed by recent sales agreements and commercialization efforts for its sleep monitoring devices.
A study published Sept. 29 in The Journal of the American Medical Association concluded that publicly available information to support the safety and effectiveness of implanted, 510(k)-cleared devices is lacking.
Aerocrine has partnered with Microsoft in a pilot project to send data from nitric oxide monitoring devices to the cloud for analysis.
Engaged Capital has stepped up its campaign to wring shareholder value from Volcano after a stock slide of more than 60% in the last year. The firm made a detailed case against the company in an open letter to the company on Sept. 29. Engaged Capital has been openly targeting the intravascular imaging and device player since it took a sizable position more than a year ago.